Purdue Ventures News Today

The Ag-Celerator, one of four funds that make up Purdue Ventures, boasts a $2 million innovation fund for startups in ag-related technologies.

Purdue contributed $250,000 as part of a larger $3 million seed funding round for Ixana, a wearable smart devices company.

Ixana’s patented high-speed Wi-R silicon chip communicates with 100 times more energy efficiency and is more secure than traditional wireless technologies

Ixana’s patented high-speed Wi-R silicon chip communicates with 100 times more energy efficiency and is more secure than traditional wireless technologies

Insignum AgTech® and Beck’s have signed an agreement to test Insignum’s innovative corn traits in Beck’s elite varieties.

Treatment in development by Adipo Therapeutics holds promise for millions who struggle with weight loss and blood glucose control...

To amplify the impact made by its faculty, staff, students and alumni, the Purdue Research Foundation and Purdue University have formed Purdue Innovates, a comprehensive system to streamline access to both (a) technology commercialization resources, such as intellectual property licensing and protection, and (b) startup support resources, including programs to launch, scale and invest in Purdue-connected startups in one cohesive structure.

Purdue Ventures, which manages three funds to support Purdue University-connected startups, has invested $250,000 in TRIO Pharmaceuticals Inc., a cancer immunotherapeutics startup founded by a Purdue University biophysics and structural biology alumnus. The company’s antibody-based therapeutics strengthens the body’s defense, the immune system, to eradicate cancer. Purdue Ventures’ investment is part of a larger $2.2 million series seed-funding round that includes investments from investor...

WEST LAFAYETTE, Ind. — Early COVID-19 pandemic suspicions about dogs’ resistance to the disease have given way to a long-haul clinical data gap as new variants of the virus have emerged. “It is not confirmed...

Early COVID-19 pandemic suspicions about dogs’ resistance to the disease have given way to a long-haul clinical data gap as new variants of the virus have emerged.